People | August 25, 2025
Parexel appoints Jim Anthony as CCO and President, Parexel Biotech
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
Subscribe To Our Newsletter & Stay Updated
